search
Back to results

Effect of CPAP on Myocardial Dysfunction in Type 2 Diabetes Mellitus and Obstructive Sleep Apnea Patients

Primary Purpose

Sleep Apnea, Obstructive, Diabetes Mellitus, Type 2, Continuous Positive Airway Pressure

Status
Completed
Phase
Not Applicable
Locations
Mexico
Study Type
Interventional
Intervention
Sham CPAP
Therapeutic CPAP
Sponsored by
Instituto Nacional de Enfermedades Respiratorias
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sleep Apnea, Obstructive focused on measuring sleep apnea, obstructive, obesity, DM2, TEI index, CPAP

Eligibility Criteria

20 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Clinical data of obstructive sleep apnea: snoring, witnessed apneas, excessive daytime somnolence.
  • Previous diagnosis of type 2 diabetes mellitus, with medical treatment according to the ADA 2012 guidelines, but only with one of the next drugs: biguanides, sulphonylurea, meglitinide, thiazolidinedione, alpha-glucosidase inhibitors.
  • Obesity, defined by a body mass index higher than 29 kilogram per square meter.

Exclusion Criteria:

  • Type 1 diabetes mellitus.
  • Insulin dependent type 2 diabetes mellitus
  • Fasting plasma glucose higher than 212 mg/dL .
  • Antecedent of myocardial infarction, heart failure or arrhythmia.
  • Obstructive sleep apnea in treatment.
  • Urgent need of CPAP treatment (public transport drivers, heavy machine operators).

Sites / Locations

  • Insituto Nacional de Enfermedades Respiratorias

Arms of the Study

Arm 1

Arm 2

Arm Type

Sham Comparator

Experimental

Arm Label

Sham CPAP

Therapeutic CPAP

Arm Description

Patients randomized to use sham CPAP via a nasal mask every night for three months, also with medical treatment for control of obesity, optimal medical treatment for diabetes mellitus.

Patients randomized to use CPAP programmed to administer automatically pressure from 4 to 20 cm H2O via a nasal mask every night for three months, also with medical treatment for control of obesity, optimal medical treatment for diabetes mellitus.

Outcomes

Primary Outcome Measures

TEI index
Cardiac performance, evaluated through TEI index.
Strain
Cardiac performance, evaluated through echocardiographic strain.

Secondary Outcome Measures

Hemoglobin A1C
Glycemic control via hemoglobin A1C, percent.
Plasma glucose.
Levels of glucose in plasma, in mg/dL.
Apnea hypopnea index
Number of events of apnea and hypopnea per hour of sleep, evaluated through an type 3 overnight sleep study,
Mean oxygen saturation
Mean value of the data of oxygen saturation reported in a type 3 overnight sleep study.
Time of hypercapnia
Number of minutes per night of sleep in which the carbon dioxide value was above 45 mmHg, as measured via transcutaneous capnography in an overnight sleep study.
Time of hypercapnia
Number of minutes per night of sleep in which the carbon dioxide value was above 45 mmHg, as measured via transcutaneous capnography in an overnight sleep study.
Mean CO2
Mean of the values of carbon dioxide during a night of sleep, as measured via transcutaneous capnography in an overnight sleep study.
Highest CO2
Highest reported value of carbon dioxide during a night of sleep, as measured via transcutaneous capnography in an overnight sleep study.
Time of saturation under 90%.
Percent of the time of duration of a type three overnight sleep study in which the SO2 was under 90%.
Mean value of arterial pressure
Mean value of systolic and diastolic arterial pressure, as measured through an ambulatory monitoring of arterial pressure for 24 hours.

Full Information

First Posted
July 14, 2017
Last Updated
February 26, 2019
Sponsor
Instituto Nacional de Enfermedades Respiratorias
Collaborators
Fundación Clínica Médica Sur, National Council of Science and Technology, Mexico
search

1. Study Identification

Unique Protocol Identification Number
NCT03221205
Brief Title
Effect of CPAP on Myocardial Dysfunction in Type 2 Diabetes Mellitus and Obstructive Sleep Apnea Patients
Official Title
Effect of Nasal CPAP on Myocardial Dysfunction and Glycemic Control in Patients With Type 2 Diabetes, Obstructive Sleep Apnea and Obesity
Study Type
Interventional

2. Study Status

Record Verification Date
February 2019
Overall Recruitment Status
Completed
Study Start Date
October 15, 2014 (Actual)
Primary Completion Date
October 24, 2017 (Actual)
Study Completion Date
November 24, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Instituto Nacional de Enfermedades Respiratorias
Collaborators
Fundación Clínica Médica Sur, National Council of Science and Technology, Mexico

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study evaluates the effect of the use of nasal CPAP in the cardiac function, measured by strain and TEI index, in patients with type 2 diabetes mellitus, obstructive sleep apnea and obesity. In order to do so, 76 patients will be studied, half will use sham CPAP and half will use therapeutic CPAP for three months, with echocardiogram, laboratory studies, ambulatory monitoring of arterial tension and sleep study before and after CPAP use.
Detailed Description
The obstructive sleep apnea syndrome (OSAS) is a disease characterized by repeated episodes of partial of total obstruction of the upper airway during sleep. It affects 3.2% of adults in Mexico City. These patients have a higher risk of suffering traffic accidents, cardiovascular diseases, a lower quality of life and premature death. The association between OSAS and heart failure is complex, but it is known that they have a higher risk of myocardial dysfunction with OR 2.4 (IC 95% 1.2 - 4.6), with higher mortality against controls. Type 2 diabetes mellitus (DM2) is a chronic metabolic disease that leads to macro and micro vascular damage, and is the first cause of mortality in Mexico (13.8% of all deaths in people older than 20 years). Its general prevalence in adults is of 7%. There is a strong association between OSAS, insulin resistance and DM2, with studies with 86% of patients with DM2 having some degree of sleep apnea reported, with 22.6% having severe OSAS. The presence of DM2 doubles the risk of cardiovascular disease in men and triples it in women, with coronary cardiac disease being the main cause of death. Patients with OSAS have altered myocardial function even in asymptomatic state, also patients with DM2 have been shown to have abnormalities in myocardial function, myocardial performance and myocardial elongation in comparison with a control group. There is no current information about the effect of treatment with CPAP on myocardial performance of patients with OSAS, DM2 and obesity.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sleep Apnea, Obstructive, Diabetes Mellitus, Type 2, Continuous Positive Airway Pressure, Myocardial Dysfunction, Echocardiography, Obesity
Keywords
sleep apnea, obstructive, obesity, DM2, TEI index, CPAP

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
78 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Sham CPAP
Arm Type
Sham Comparator
Arm Description
Patients randomized to use sham CPAP via a nasal mask every night for three months, also with medical treatment for control of obesity, optimal medical treatment for diabetes mellitus.
Arm Title
Therapeutic CPAP
Arm Type
Experimental
Arm Description
Patients randomized to use CPAP programmed to administer automatically pressure from 4 to 20 cm H2O via a nasal mask every night for three months, also with medical treatment for control of obesity, optimal medical treatment for diabetes mellitus.
Intervention Type
Device
Intervention Name(s)
Sham CPAP
Intervention Description
CPAP (ResMed AutoSet S9 with humidifier) to be used by the participant via nasal mask and tube, programmed to apply 0.5 cmH2O (measured at the nasal mask) via a resistance to assure the lack of distal pressure.
Intervention Type
Device
Intervention Name(s)
Therapeutic CPAP
Intervention Description
Use of CPAP (ResMed AutoSet S9 with humidifier) through nasal mask and tube with automatized pressure from 4 to 20 cmH2O.
Primary Outcome Measure Information:
Title
TEI index
Description
Cardiac performance, evaluated through TEI index.
Time Frame
After 3 months of CPAP use.
Title
Strain
Description
Cardiac performance, evaluated through echocardiographic strain.
Time Frame
After 3 months of CPAP use.
Secondary Outcome Measure Information:
Title
Hemoglobin A1C
Description
Glycemic control via hemoglobin A1C, percent.
Time Frame
After three months of CPAP use.
Title
Plasma glucose.
Description
Levels of glucose in plasma, in mg/dL.
Time Frame
After 3 months of CPAP use.
Title
Apnea hypopnea index
Description
Number of events of apnea and hypopnea per hour of sleep, evaluated through an type 3 overnight sleep study,
Time Frame
After 3 months CPAP use.
Title
Mean oxygen saturation
Description
Mean value of the data of oxygen saturation reported in a type 3 overnight sleep study.
Time Frame
After 3 months of CPAP use.
Title
Time of hypercapnia
Description
Number of minutes per night of sleep in which the carbon dioxide value was above 45 mmHg, as measured via transcutaneous capnography in an overnight sleep study.
Time Frame
After 3 months of CPAP use.
Title
Time of hypercapnia
Description
Number of minutes per night of sleep in which the carbon dioxide value was above 45 mmHg, as measured via transcutaneous capnography in an overnight sleep study.
Time Frame
After three months CPAP use.
Title
Mean CO2
Description
Mean of the values of carbon dioxide during a night of sleep, as measured via transcutaneous capnography in an overnight sleep study.
Time Frame
After three months CPAP use
Title
Highest CO2
Description
Highest reported value of carbon dioxide during a night of sleep, as measured via transcutaneous capnography in an overnight sleep study.
Time Frame
After three months CPAP use
Title
Time of saturation under 90%.
Description
Percent of the time of duration of a type three overnight sleep study in which the SO2 was under 90%.
Time Frame
After 3 months CPAP use
Title
Mean value of arterial pressure
Description
Mean value of systolic and diastolic arterial pressure, as measured through an ambulatory monitoring of arterial pressure for 24 hours.
Time Frame
After 3 months of CPAP use

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Clinical data of obstructive sleep apnea: snoring, witnessed apneas, excessive daytime somnolence. Previous diagnosis of type 2 diabetes mellitus, with medical treatment according to the ADA 2012 guidelines, but only with one of the next drugs: biguanides, sulphonylurea, meglitinide, thiazolidinedione, alpha-glucosidase inhibitors. Obesity, defined by a body mass index higher than 29 kilogram per square meter. Exclusion Criteria: Type 1 diabetes mellitus. Insulin dependent type 2 diabetes mellitus Fasting plasma glucose higher than 212 mg/dL . Antecedent of myocardial infarction, heart failure or arrhythmia. Obstructive sleep apnea in treatment. Urgent need of CPAP treatment (public transport drivers, heavy machine operators).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Armando R Castorena-Maldonado, MD
Organizational Affiliation
Instituto Nacional de Enfermedades Respiratorias
Official's Role
Principal Investigator
Facility Information:
Facility Name
Insituto Nacional de Enfermedades Respiratorias
City
Mexico City
State/Province
Delegacion Tlalpan
ZIP/Postal Code
14080
Country
Mexico

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
20932716
Citation
Ernande L, Rietzschel ER, Bergerot C, De Buyzere ML, Schnell F, Groisne L, Ovize M, Croisille P, Moulin P, Gillebert TC, Derumeaux G. Impaired myocardial radial function in asymptomatic patients with type 2 diabetes mellitus: a speckle-tracking imaging study. J Am Soc Echocardiogr. 2010 Dec;23(12):1266-72. doi: 10.1016/j.echo.2010.09.007. Epub 2010 Oct 8.
Results Reference
background
PubMed Identifier
19892057
Citation
Ng AC, Delgado V, Bertini M, van der Meer RW, Rijzewijk LJ, Shanks M, Nucifora G, Smit JW, Diamant M, Romijn JA, de Roos A, Leung DY, Lamb HJ, Bax JJ. Findings from left ventricular strain and strain rate imaging in asymptomatic patients with type 2 diabetes mellitus. Am J Cardiol. 2009 Nov 15;104(10):1398-401. doi: 10.1016/j.amjcard.2009.06.063. Epub 2009 Sep 26.
Results Reference
background
PubMed Identifier
15316450
Citation
Marwick TH. Tissue Doppler imaging for evaluation of myocardial function in patients with diabetes mellitus. Curr Opin Cardiol. 2004 Sep;19(5):442-6. doi: 10.1097/01.hco.0000131535.32657.87.
Results Reference
background
Citation
Carrillo-Alduenda JL, Arredondo del Bosque F, Reyes-Zúñiga M, Barabia Ortega B, Yáñez-Gutiérrez L, Torre-Bouscoulet L, Castorena-Maldonado A. Índice de funcionamiento miocárdico en pacientes con síndrome de apnea obstructiva del sueño. Neumología y cirugía de tórax. 2009;68(3):100-105
Results Reference
background
PubMed Identifier
20009388
Citation
Tugcu A, Yildirimturk O, Tayyareci Y, Demiroglu C, Aytekin S. Evaluation of subclinical right ventricular dysfunction in obstructive sleep apnea patients using velocity vector imaging. Circ J. 2010 Feb;74(2):312-9. doi: 10.1253/circj.cj-09-0562. Epub 2009 Dec 15.
Results Reference
background

Learn more about this trial

Effect of CPAP on Myocardial Dysfunction in Type 2 Diabetes Mellitus and Obstructive Sleep Apnea Patients

We'll reach out to this number within 24 hrs